top of page
dreamstimemaximum_88001888_lower mb.jpg
icons_quality policy.png

Quality policy

Interlinked AB is a medical device company with a focus on need-based product development through to commercialisation in accordance with Interlinked’s QMS and applicable regulatory requirements.

 

Interlinked provides breakaway connectors to be used as value enhancing components for medical tubes reducing catheter dislodgement.

ReLink platform

tada group relink working.gif

ReLink is a patented breakaway connector, designed to prevent mechanical complications such as dislodgement, thereby providing increased safety for patients and nurses. It comprises a weak link concept to reduce IV catheter dislodgement in combination with self-sealable valves to prevent spill of IV fluids, medicine, and blood.

Child-Hand-Good.jpg

Advantages for patients

  • Minimises risks of IV catheter complications such as dislodgement

  • Reduces patient injuries and risk for infections

  • Supports accurate drug delivery

AdobeStock_130573118 lower mb.jpg

Advantages for nurses

  • Reduces risk of toxic drug exposure

  • Reduces risk of blood exposure

  • Reduces unnecessary workload and unlocks valuable nursing hours

Tada Group feature 1.png
Tada Group feature 2.png
Tada Group feature 3.png
Tada Group feature 4.png

ReLink features

Breakaway connector

A non-invasive method to reduce
IV catheter dislodgement

Self-sealing valves

The two halves are equipped with self-sealing valves 

Reconnectable

The two halves reconnect to
rapidly resume therapy

Research support

The project has received funding from the European Union's Horizon 2020 research and innovation programme under EIC Accelerator grant, Fast Track to Innovation grant and from the Eurostars-2 Joint Programme with co-funding from the European Union's Horizon 2020 research and innovation programme

eithealth.png
1602248683_vinnovas-logotyp-i-farg-mellanupplost.png

Sustainability

Our innovation not only addresses healthcare and patient safety, but also the wider concerns of European and global importance as outlined in the 2030 agenda for sustainable development.

Annual Report 2022 v10-01_edited.jpg
Goal 3: Good health and well-being 

ReLink is a solution that disrupts the state-of-the-art of IV therapy. The elderly patients, psychiatric patients, as well as paediatric patients will particularly benefit from the improvements that ReLink offers.

Annual Report 2022 v10-02.jpg
Goal 6: Clean water and sanitation

ReLink aids in curbing hazardous chemical pollution, lowering medication wastage, and promoting affordable healthcare solutions, thus addressing global challenges and enhancing safety.

Annual Report 2022 v10-03.jpg
Goal 8: Decent work and economic growth

ReLink enhances global healthcare by saving time and costs, preventing spills, ensuring safety, and creating a positive working environment for healthcare professionals, while being adaptable for home care.

Annual Report 2022 v10-04.jpg
Goal 12: Responsible consumption and production

ReLink will align towards improper waste handling, not only for medicine and chemicals, but also by saving plastic waste annually in Europe and USA.

bottom of page